Biodel (BIOD) Gets Orphan Designation Suggestion from EMA COMP for CHI Treatment Glucagon

Biodel Inc. (Nasdaq: BIOD) reports that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that Biodel's Stabilized Glucagon for the treatment of congenital hyperinsulinism (CHI) be granted Orphan Medicinal Product Designation. The COMP's recommendation to the European Commission generally results in a ratification of the COMP opinion by the European Commission one to two months following the announcement by the COMP. Orphan designation qualifies the sponsor of the product for fee reductions, protocol assistance, centralized application procedure and access to 10 years marketing exclusivity once authorized, according to the Orphan Drug Regulation.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
• Chelsea Therapeutics (CHTP) Completes End-of-Review Meeting with FDA Over Northera NDA

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter